Vyvgart access in Pakistan: the DRAP named-patient pathway
How Pakistan patients legally obtain Vyvgart (efgartigimod alfa) when the locally registered indication, presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Vyvgart (efgartigimod alfa) is a neonatal Fc receptor (FcRn) antagonist developed by Argenx. It is approved by the US FDA for generalised myasthenia gravis in adults who are AChR antibody-positive, chronic inflammatory demyelinating polyneuropathy (CIDP). The standard regimen is 10 mg/kg IV weekly for 4-week cycles, repeat cycles based on clinical response; Hytrulo subcutaneous 1,008 mg weekly cycles. Vyvgart is available in the global pharmaceutical supply chain in 400 mg per 20 mL IV vial; Vyvgart Hytrulo subcutaneous coformulation with hyaluronidase. The drug may or may not be locally registered in Pakistan, and even when registered, a Pakistan family asking for Vyvgart is often asking for a precise version of it (specific indication, specific presentation, specific schedule) that the local market has not caught up to. Reserve Meds coordinates the US-side sourcing, the validated cold-chain logistics, and the documentation packet your physician needs.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Pakistan patients need Vyvgart through the named-patient pathway
The Drug Regulatory Authority of Pakistan (DRAP), established under the DRAP Act 2012 and operating alongside the Drugs Act 1976, administers personal-import permissions for unregistered medicines. A treating physician licensed by the Pakistan Medical Commission applies for the import permission through DRAP when the medicine is approved by a recognised reference regulator (US FDA, EMA, MHRA, PMDA, or Health Canada) and a clinically equivalent locally registered alternative is not available.
Several patterns drive these cases: indication lag against the FDA label; specialty biologic and oncology cases where DRAP-registered local stock is constrained; payer denials by private insurers; and Pakistani families using cross-border supply for the precise FDA-labeled originator product or for indications the local route has not caught up to. For Vyvgart specifically, the named-patient pathway exists to handle exactly the situations the local registered route cannot: a newer FDA indication that has not yet propagated to Pakistan labeling, a presentation or strength the local agent does not reliably carry, a payer denial that is uneconomic to appeal, or a biomarker-defined regimen where the prescriber's clinical judgement runs ahead of the local label's molecular language. In each pattern, the named-patient pathway is the mechanism that connects a Pakistan-licensed physician's clinical decision with US-sourced, FDA-labeled Vyvgart for a specific patient.
Vyvgart was FDA-approved in December 2021 for generalised myasthenia gravis in AChR antibody-positive adults and expanded to CIDP in June 2024. Vyvgart Hytrulo subcutaneous coformulation with hyaluronidase (FDA June 2023) is the patient-preferred administration for many cases. Local registration may carry the IV formulation but not the subcutaneous Hytrulo presentation.
The DRAP named-patient pathway for Vyvgart
A complete application typically includes a clinical justification letter from the treating physician (diagnosis, severity or stage, prior therapies, biomarker results where relevant, why Vyvgart is appropriate, why the locally available alternative is not suitable for this case); the treating physician's Pakistan license verification (issued by Pakistan Medical Commission (PMC)); an anonymised patient identifier where the regulator submission allows; full product details (brand name Vyvgart, generic efgartigimod alfa, manufacturer Argenx, strength 400 mg per 20 mL IV vial; Vyvgart Hytrulo subcutaneous coformulation with hyaluronidase, quantity requested calibrated to the planned cycles or treatment duration); the destination dispensing facility name, license number, and pharmacy in charge; and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy, including cold-chain handling at 2 to 8 degrees Celsius from the US manufacturer through to the dispensing pharmacy.
For Vyvgart, the clinical justification typically rests on documentation of AChR antibody status for gMG; nerve conduction and clinical for CIDP where applicable, line of therapy and prior treatments, and a clear statement of why this medicine is the appropriate next step in this patient's care.
Approval timelines for routine cases are typically 15 to 30 business days from a complete filing. Complex cases (rare indication, paediatric application, larger multi-cycle quantities, gene therapy or cell therapy logistics, first-import scrutiny on a presentation new to the local route) can extend to 5 to 8 weeks. The DRAP retains discretion on timing, and we do not promise specific durations.
Where Vyvgart gets dispensed in Pakistan
A small group of Pakistan institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that fit this profile include Shaukat Khanum Memorial Cancer Hospital and Research Centre in Lahore (cancer referral), Aga Khan University Hospital in Karachi (JCI-accredited tertiary referral), Liaquat National Hospital in Karachi, Hashmanis Hospital, South City Hospital, The Indus Hospital network, Doctors Hospital Lahore, Hameed Latif Hospital, Pakistan Kidney and Liver Institute in Lahore, Shifa International Hospital in Islamabad, Maroof International Hospital, and Quaid-e-Azam International Hospital.
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a Karachi, Lahore, and Islamabad-based specialty importer that holds a pharmaceutical establishment license and files the DRAP application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's pharmacy under chain-of-custody documentation, where the patient receives the infusion under standard hospital or day-care nursing supervision.
Real cost picture for Vyvgart in Pakistan
US WAC for Vyvgart is approximately USD 6,400 per 400 mg vial, which translates to USD 225,000 to USD 350,000 per year (cycle-based). The Pakistani rupee floats with material volatility; a working reference rate of approximately 280 PKR to 1 USD applies for illustrative conversion, but live quotes track current FX, so the annual reference range converts accordingly when expressed in PKR at US WAC equivalents.
International validated cold-chain logistics typically run USD 500 to USD 1,700 (varies materially with PKR volatility) per shipment depending on destination city, urgency, and pack size. Pakistan customs and DRAP permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the insurance side, each Pakistan insurer assesses named-patient imports case by case. Local payer cover is administered through Adamjee Health, EFU Life, Jubilee Life, IGI General, State Life, TPL Life, Salaam Takaful Pakistan, and Sehat Sahulat Programme for eligible families. We do not promise coverage from any insurer. The US manufacturer copay programmes and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage where it applies.
Clinical evidence behind Vyvgart
Vyvgart's pivotal ADAPT (gMG, MG-ADL responder analysis) and ADAPT+ extension data anchor the gMG indication. ADHERE (CIDP) supports the 2024 expansion. The Hytrulo subcutaneous bioequivalence (ADAPT-SC) made same-day cycle administration outpatient-feasible.
Typical timeline for Vyvgart in Pakistan
DRAP routine processing is typically 15 to 30 business days from a complete filing. For Vyvgart specifically, cold-chain shipment adds 2 to 3 days versus an ambient small molecule because validated thermal packaging, continuous temperature monitoring, and customs clearance scheduled to avoid extreme-heat exposure are non-negotiable. End-to-end, most cases complete within 3 to 6 weeks from first complete documentation to dispensing or first dose. For longer treatment courses, we coordinate cycle-by-cycle or quarterly resupply so the patient never approaches an empty pharmacy shelf.
What your physician needs to provide
For a Pakistan-licensed physician prescribing Vyvgart through the DRAP pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's diagnosis with relevant staging or severity language for the indication, the prior therapy history, the rationale for Vyvgart as the appropriate next step, and the precise FDA-labeled regimen (dose, route, frequency, expected duration). For Vyvgart specifically, the FDA-approved regimen is 10 mg/kg IV weekly for 4-week cycles, repeat cycles based on clinical response; Hytrulo subcutaneous 1,008 mg weekly cycles.
For Vyvgart, the relevant molecular or laboratory documentation includes AChR antibody status for gMG; nerve conduction and clinical for CIDP. The letter references the test results that establish the patient's eligibility for the FDA-labeled indication. The treating physician's Pakistan license number, the dispensing facility license number, and the pharmacy in charge complete the package. Monitoring requirements relevant to Vyvgart (baseline labs, imaging cadence, adverse-event surveillance) are stated in the letter and operationalised by the prescribing physician's team.
Monitoring for Vyvgart: Anti-AChR antibody status confirmation at baseline (for gMG), IgG levels during therapy (FcRn antagonism transiently reduces IgG, including pathogenic IgG), infection surveillance, and ongoing clinical assessment by neurology with disease-specific scales. Adverse-event profile: Headache, upper respiratory tract infections, urinary tract infections, herpes infections, infusion reactions (IV) and injection-site reactions (Hytrulo). IgG reduction can predispose to infection.
Common questions about Vyvgart in Pakistan
Will my insurer cover this? Each Pakistan insurer (Adamjee Health, EFU Life, Jubilee Life, IGI General, State Life, TPL Life, Salaam Takaful Pakistan, and Sehat Sahulat Programme for eligible families) assesses named-patient imports case by case. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is Vyvgart already locally registered in Pakistan? Local registration status can shift over time; Vyvgart may already be on the Pakistan register for some indications but not others, or the registered presentation may not match what the prescriber needs. The DRAP pathway exists precisely to bridge these gaps and is the cleanest legal route when the local supply chain does not match the prescription.
What about competitors? Alternatives in the same therapeutic class include rozanolixizumab (Rystiggo, FcRn), eculizumab (Soliris), ravulizumab (Ultomiris), zilucoplan (Zilbrysq), rituximab, IVIG, plasma exchange, pyridostigmine, prednisone, azathioprine, mycophenolate. Choice depends on the patient's full profile, prior therapy, biomarker status, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed.
How does the cold chain work? This medicine requires cold-chain handling at 2 to 8 degrees Celsius from manufacture through to dispensing. Reserve Meds uses validated thermal packaging with continuous temperature logging. Customs clearance is scheduled to avoid prolonged tarmac exposure. The cold chain is broken only at the dispensing pharmacy.
Will my US manufacturer assistance program help? US patient assistance programs (PAP), copay cards, and bridge programs from Merck, Pfizer, AstraZeneca, Lilly, Roche, Genentech, Novartis, AbbVie, Janssen, Gilead, Biogen, BMS, and other manufacturers are generally restricted to US residents with US prescriptions filled at US pharmacies. Cross-border patients pay cash or use local payer cover.
What if treatment is multi-year? For long-running treatment, we coordinate cycle-by-cycle or quarterly resupply through the same DRAP pathway, with each shipment authorised against the same physician documentation set updated for the current cycle. Patients never need to navigate the supply chain themselves.
Where is the medicine actually administered? Infusion is administered at a hospital or day-care infusion suite under nursing supervision with vital-sign monitoring. The dispensing pharmacy releases the vial only to the infusion suite on the day of administration. Home administration is not appropriate for IV infusion of this product.
What if my physician is at a smaller clinic that does not import directly? The standard pattern is to route through a Karachi, Lahore, and Islamabad-based specialty importer that holds a pharmaceutical establishment license. The importer files the DRAP application on behalf of the prescribing physician, takes delivery of the medicine, and transfers it under chain-of-custody to the prescribing facility's pharmacy.
Operational notes for the DRAP workflow
Operationally, the DRAP personal-import permission is filed by the treating physician through DRAP via the Federal Drug Inspector channel. Common reasons for delay are FX availability and import-clearance timing, incomplete documentation of the unmet need, or chain-of-custody plans that do not specify continuous temperature logging. Karachi and Lahore have the most developed specialty-import infrastructure and the highest concentration of tertiary referral centres comfortable with the workflow.
Where Reserve Meds fits in Vyvgart cases
Reserve Meds is a US-based concierge coordinator. We do not replace your prescribing physician, we do not replace the DRAP, and we do not replace your dispensing pharmacy. For Vyvgart specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated cold-chain logistics with appropriate temperature monitoring into Pakistan, plan cycle-by-cycle resupply across longer treatment courses, and assign a single named coordinator through the case. Standard NPP coordination under our cold-chain biologic playbook applies.
Next step
If your Pakistan physician has prescribed Vyvgart and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.